Novavax Inc (NVAX) shareholders
Close on Nov 17, 2026Market cap $1.31BP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| BlackRock, Inc. | 13,450,411 | 8.40% | 13G (passive) amendment | Dec 31, 2024 |
| Himanshu H. Shah Joint filing with Shah Capital Management (6.39%) | 10,656,964 | 6.46% | 13D (active) amendment | Oct 16, 2026 |
| State Street Corporation | 8,827,707 | 5.40% | 13G (passive) | Sep 30, 2026 |
| Vanguard Capital Management | 8,305,681 | 5.09% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of NVAX | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Shah Capital Management | 14,165,577 | 8.59% | $133.44M | −679,520 | 25.36% |
| BlackRock, Inc. | 13,946,881 | 8.46% | $131.38M | +1,102,562 | 0.00% |
| State Street Corp | 11,740,550 | 7.12% | $110.60M | +2,770,032 | 0.00% |
| Vanguard Portfolio Management LLC | 7,607,996 | 4.61% | $71.67M | +456,371 | 0.00% |
| Vanguard Capital Management LLC | 7,257,449 | 4.40% | $68.37M | +127,302 | 0.00% |
| Sanofi | 6,880,481 | 4.17% | $64.81M | – | 12.14% |
| D. E. Shaw & Co., Inc. | 5,650,905 | 3.43% | $53.23M | −2,058,953 | 0.03% |
| Geode Capital Management, LLC | 4,207,370 | 2.55% | $39.64M | +308,957 | 0.00% |
| Two Sigma Investments, LP | 4,091,043 | 2.48% | $38.54M | +3,476,244 | 0.03% |
| Coatue Management LLC | 3,836,986 | 2.33% | $36.14M | – | 0.07% |
| Bank Of America Corp /De/ | 3,416,235 | 2.07% | $32.18M | −3,220,978 | 0.00% |
| Goldman Sachs Group Inc | 3,007,756 | 1.82% | $28.33M | +1,598,310 | 0.00% |
| UBS Group AG | 1,869,659 | 1.13% | $17.61M | −2,608,042 | 0.00% |
| Millennium Management LLC | 1,768,163 | 1.07% | $16.66M | −2,084,382 | 0.01% |
| Citadel Advisors LLC | 1,695,313 | 1.03% | $15.97M | +571,567 | 0.00% |
| Allianz Asset Management GmbH | 1,579,200 | 0.96% | $14.88M | −280,654 | 0.01% |
| Northern Trust Corp | 1,448,108 | 0.88% | $13.64M | −61,218 | 0.00% |
| TSP Capital Management Group, LLC | 1,419,365 | 0.86% | $13.37M | New | 3.20% |
| Charles Schwab Investment Management Inc | 1,346,607 | 0.82% | $12.69M | −26,898 | 0.00% |
| Vanguard Fiduciary Trust Co | 1,085,100 | 0.66% | $10.22M | −22,086 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 267 | 117M | 71.2% | 44 / 77 | 87 / 31 | 18M | 18M |
| Q1 2026 | 258 | 117M | 70.7% | 55 / 73 | 73 / 26 | 29M | 13M |
| Q4 2025 | 235 | 117M | 70.7% | 35 / 70 | 77 / 43 | 26M | 12M |
| Q3 2025 | 249 | 103M | 62.6% | 46 / 73 | 75 / 46 | 10M | 9M |
| Q2 2025 | 251 | 102M | 61.6% | 51 / 80 | 52 / 43 | 15M | 12M |
| Q1 2025 | 246 | 99M | 59.8% | 51 / 69 | 66 / 36 | 13M | 17M |
| Q4 2024 | 234 | 103M | 62.3% | 41 / 80 | 54 / 41 | 23M | 14M |
| Q3 2024 | 237 | 94M | 56.9% | 42 / 66 | 64 / 33 | 28M | 6M |
| Q2 2024 | 230 | 84M | 50.7% | 59 / 68 | 57 / 29 | 27M | 24M |
| Q1 2024 | 202 | 81M | 49.0% | 33 / 72 | 43 / 28 | 9M | 13M |
| Q4 2023 | 199 | 85M | 51.7% | 27 / 66 | 52 / 51 | 32M | 8M |
| Q3 2023 | 225 | 62M | 37.5% | 45 / 64 | 56 / 32 | 11M | 16M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
164 funds held NVAX in Q2 2026, 81% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of NVAX | Value | % of fund | As of |
|---|---|---|---|---|---|
| State Street(R) SPDR(R) S&P(R) Biotech ETF | 7,529,392 | 4.56% | $70.93M | 0.66% | Jun 30, 2026 |
| Vanguard Total Stock Market Index Fund | 5,197,170 | 3.15% | $48.96M | 0.00% | Jun 30, 2026 |
| iShares Russell 2000 ETF | 3,914,013 | 2.37% | $36.87M | 0.04% | Jun 30, 2026 |
| Vanguard Small-Cap Index Fund | 3,766,470 | 2.28% | $35.48M | 0.02% | Jun 30, 2026 |
| Vanguard Small-Cap Growth Index Fund | 2,163,104 | 1.31% | $20.38M | 0.04% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 1,893,260 | 1.15% | $17.83M | 0.02% | Jun 30, 2026 |
| Fidelity Small Cap Index Fund | 1,668,051 | 1.01% | $12.21M | 0.04% | Jul 31, 2026 |
| iShares Russell 2000 Value ETF | 1,434,059 | 0.87% | $13.51M | 0.09% | Jun 30, 2026 |
| iShares Biotechnology ETF | 1,110,696 | 0.67% | $10.46M | 0.12% | Jun 30, 2026 |
| PIMCO RAE US Small Fund | 1,015,460 | 0.62% | $9.57M | 0.25% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 840,526 | 0.51% | $9.22M | 0.02% | May 31, 2026 |
| Schwab U.S. Small-Cap ETF | 785,989 | 0.48% | $8.62M | 0.04% | May 31, 2026 |
| Vanguard Russell 2000 Index Fund | 769,134 | 0.47% | $8.44M | 0.05% | May 31, 2026 |
| Federated Hermes MDT Small Cap Core Fund | 692,795 | 0.42% | $5.07M | 0.23% | Jul 31, 2026 |
| Fidelity Enhanced Small Cap Core ETF | 533,357 | 0.32% | $5.02M | 0.09% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| John C. Jacobs | President and CEO, Director | 225,680 | 0.14% | Mar 9, 2026 |
| Robert Edward Walker | EVP, R&D | 34,386 | 0.02% | Apr 16, 2026 |
| Elaine O'Hara | EVP, Chief Strategy Officer | 157,071 | 0.10% | Mar 9, 2026 |
| James Patrick Kelly | EVP, CFO and Treasurer | 130,599 | 0.08% | Mar 9, 2026 |
| Mark J. Casey | EVP, Chief Legal Officer | 101,445 | 0.06% | Mar 9, 2026 |
| Ruxandra Draghia-Akli | EVP, Research & Development | 23,563 | 0.01% | Mar 9, 2026 |
| John Trizzino | President and COO | 82,015 | 0.05% | Mar 11, 2025 |
| John W. Shiver | Director | 7,947 | 0.00% | Jun 23, 2026 |
| David M. Mott | Director | 79,770 | 0.05% | Jun 23, 2026 |
| Rachel K. King | Director | 45,170 | 0.03% | Jun 23, 2026 |
| Margaret G. McGlynn | Director | 44,468 | 0.03% | Jun 23, 2026 |
| Gregg H. Alton | Director | 47,685 | 0.03% | Jun 23, 2026 |
| Richard Douglas | Director | 73,220 | 0.04% | Jun 23, 2026 |
| Charles W. Newton | Director | 9,520 | 0.01% | Jun 23, 2026 |
| Richard J. Rodgers | Director | 47,370 | 0.03% | Jun 23, 2026 |
| James F. Young | Director | 53,260 | 0.03% | Jan 2, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Richard Douglas Director | Jun 20, 2026 | Option exercise | +18,880 | – | – | 73,220 |
| Rachel K. King Director | Jun 20, 2026 | Option exercise | +18,880 | – | – | 44,070 |
| Gregg H. Alton Director | Jun 20, 2026 | Option exercise | +18,880 | – | – | 47,685 |
| Richard J. Rodgers Director | Jun 20, 2026 | Option exercise | +18,880 | – | – | 47,370 |
| Margaret G. McGlynn Director | Jun 20, 2026 | Option exercise | +18,880 | – | – | 44,468 |
| David M. Mott Director | Jun 20, 2026 | Option exercise | +18,880 | – | – | 79,770 |
| Charles W. Newton Director | Apr 25, 2026 | Option exercise | +9,520 | – | – | 9,520 |
| John W. Shiver Director | Mar 10, 2026 | Option exercise | +7,947 | – | – | 7,947 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 7, 2026 | Tax withholding | −5,904 | $9.98 | $58.92K | 130,599 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 7, 2026 | Option exercise | +12,223 | – | – | 136,503 |
| Mark J. Casey EVP, Chief Legal Officer | Mar 3, 2026 | Option exercise | +37,500 | – | – | 101,445 |
| Mark J. Casey EVP, Chief Legal Officer | Mar 3, 2026 | Tax withholding | −11,378 | $9.49 | $107.98K | 90,067 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 3, 2026 | Option exercise | +56,334 | – | – | 157,071 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 3, 2026 | Tax withholding | −22,429 | $9.49 | $212.85K | 134,642 |
| Ruxandra Draghia-Akli EVP, Research & Development | Mar 3, 2026 | Tax withholding | −11,313 | $9.49 | $107.36K | 23,563 |
| Ruxandra Draghia-Akli EVP, Research & Development | Mar 3, 2026 | Option exercise | +26,667 | – | – | 34,876 |
| John C. Jacobs President and CEO, Director | Mar 3, 2026 | Tax withholding | −69,288 | $9.49 | $657.54K | 225,680 |
| John C. Jacobs President and CEO, Director | Mar 3, 2026 | Option exercise | +150,167 | – | – | 264,130 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 3, 2026 | Tax withholding | −20,850 | $9.49 | $197.87K | 124,280 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 3, 2026 | Option exercise | +43,167 | – | – | 145,130 |
| John C. Jacobs President and CEO, Director | Mar 1, 2026 | Option exercise | +83,333 | – | – | 264,130 |
| John C. Jacobs President and CEO, Director | Mar 1, 2026 | Tax withholding | −38,450 | $10.14 | $389.88K | 225,680 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 1, 2026 | Option exercise | +58,666 | – | – | 130,299 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 1, 2026 | Tax withholding | −28,366 | $10.14 | $287.63K | 101,963 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2026 | Tax withholding | −10,969 | $10.14 | $111.23K | 100,737 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2026 | Option exercise | +19,600 | – | – | 77,081 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2026 | Tax withholding | −5,375 | $10.14 | $54.50K | 71,706 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2026 | Option exercise | +40,000 | – | – | 111,706 |
| Mark J. Casey EVP, Chief Legal Officer | Mar 1, 2026 | Option exercise | +4,000 | – | – | 65,159 |
| Mark J. Casey EVP, Chief Legal Officer | Mar 1, 2026 | Tax withholding | −1,214 | $10.14 | $12.31K | 63,945 |
| John C. Jacobs President and CEO, Director | Jan 23, 2026 | Option exercise | +83,197 | – | – | 219,929 |
| John C. Jacobs President and CEO, Director | Jan 23, 2026 | Tax withholding | −39,132 | $9.17 | $358.84K | 180,797 |
| Mark J. Casey EVP, Chief Legal Officer | Dec 11, 2025 | Option exercise | +41,899 | – | – | 73,972 |
| Mark J. Casey EVP, Chief Legal Officer | Dec 11, 2025 | Tax withholding | −12,713 | $6.69 | $85.05K | 61,159 |
| Ruxandra Draghia-Akli Section 16 | Nov 11, 2025 | Option exercise | +14,257 | – | – | 14,257 |
| Ruxandra Draghia-Akli Section 16 | Nov 11, 2025 | Tax withholding | −6,048 | $7.40 | $44.76K | 8,209 |
| Richard J. Rodgers Director | Oct 29, 2025 | Option exercise | +3,800 | – | – | 28,490 |
| Gregg H. Alton Director | Jun 12, 2025 | Option exercise | +10,420 | – | – | 28,805 |
| Margaret G. McGlynn Director | Jun 12, 2025 | Option exercise | +10,420 | – | – | 25,588 |
| Richard Douglas Director | Jun 12, 2025 | Option exercise | +10,420 | – | – | 54,340 |
| Richard J. Rodgers Director | Jun 12, 2025 | Option exercise | +10,420 | – | – | 24,690 |
| Rachel K. King Director | Jun 12, 2025 | Option exercise | +10,420 | – | – | 25,190 |
| David M. Mott Director | Jun 12, 2025 | Option exercise | +10,420 | – | – | 60,890 |
| John Trizzino President and COO | Mar 7, 2025 | Option exercise | +28,890 | – | – | 82,015 |
| John Trizzino President and COO | Mar 7, 2025 | Tax withholding | −13,954 | $8.34 | $116.38K | 68,061 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 7, 2025 | Tax withholding | −5,904 | $8.34 | $49.24K | 69,251 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 7, 2025 | Option exercise | +12,223 | – | – | 75,155 |
| John C. Jacobs President and CEO, Director | Mar 1, 2025 | Tax withholding | −38,451 | $8.33 | $320.30K | 136,732 |
| John C. Jacobs President and CEO, Director | Mar 1, 2025 | Option exercise | +83,334 | – | – | 175,183 |
| John Trizzino President and COO | Mar 1, 2025 | Tax withholding | −23,185 | $8.33 | $193.13K | 53,125 |
| John Trizzino President and COO | Mar 1, 2025 | Option exercise | +48,000 | – | – | 76,310 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2025 | Tax withholding | −5,375 | $8.33 | $44.77K | 68,450 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2025 | Tax withholding | −10,969 | $8.33 | $91.37K | 57,481 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2025 | Option exercise | +40,000 | – | – | 73,825 |
| Elaine O'Hara EVP, Chief Strategy Officer | Mar 1, 2025 | Option exercise | +19,600 | – | – | 33,825 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 1, 2025 | Tax withholding | −28,337 | $8.33 | $236.05K | 62,932 |
| James Patrick Kelly EVP, CFO and Treasurer | Mar 1, 2025 | Option exercise | +58,667 | – | – | 91,269 |
| Mark J. Casey EVP, Chief Legal Officer | Mar 1, 2025 | Tax withholding | −1,214 | $8.33 | $10.11K | 31,973 |
| Mark J. Casey EVP, Chief Legal Officer | Mar 1, 2025 | Option exercise | +4,000 | – | – | 33,187 |
| John C. Jacobs President and CEO, Director | Jan 23, 2025 | Tax withholding | −38,873 | $9.55 | $371.24K | 91,849 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Novavax's stock actually held short. Settlement fails (shares not delivered on time) peaked at 606,892 shares on Aug 28, 2026 over the last 90 days.
Planned insider sales
Notices of proposed sale filed on Form 144 before shares are sold
| Seller | Filed | Shares | Market value | Planned sale | Acquired through |
|---|---|---|---|---|---|
| Ruxandra Draghia-Akli Former Officer | May 27, 2026 | 21,383 | $235.41K | May 27, 2026 | Stock Plan Activity |
| Ruxandra Draghia-Akli Former Officer | May 7, 2026 | 30,000 | $296.08K | May 7, 2026 | Stock Plan Activity |
| James F. Young Former Director | May 19, 2025 | 10,000 | $75.88K | May 19, 2025 | Stock Plan Activity |
| James F. Young Former Director | Apr 14, 2025 | 4,000 | $24.41K | Apr 14, 2025 | Stock Plan Activity |
| James F. Young Director | Jan 2, 2025 | 10,000 | $84.80K | Dec 24, 2024 | Stock Plan Activity |
| James F. Young Director | Dec 26, 2024 | 10,000 | $84.80K | Dec 24, 2024 | Stock Plan Activity |
| Rachel K. King Board Member | Dec 13, 2024 | 4,150 | $37.35K | Dec 13, 2024 | Market purchase |
| Filip Dubovsky Officer | Sep 18, 2024 | 7,335 | $95.33K | Sep 18, 2024 | Stock Plan Activity |
| James F. Young Director | Jun 18, 2024 | 15,000 | $205.65K | Jun 18, 2024 | Stock Plan Activity |
| Filip Dubovsky Officer | Jun 17, 2024 | 13,904 | $201.19K | Jun 17, 2024 | Stock Plan Activity |
| Filip Dubovsky Officer | May 14, 2024 | 47,312 | $657.39K | May 14, 2024 | Stock Plan Activity |
See a number that looks wrong?